Rho kinase inhibition: A new approach for treating diabetic nephropathy?

Diabetes

Volumn 57, Issue 3, 2008, Pages 532-533

  Bach, Leon A ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; FASUDIL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; RHO KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; AMIDE; DRUG DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; RHO KINASE;

ALBUMINURIA; DIABETIC NEPHROPATHY; DRUG EFFICACY; GLOMERULUS BASEMENT MEMBRANE; GLUCOSE BLOOD LEVEL; MESANGIUM; NONHUMAN; NOTE; PRIORITY JOURNAL; RENAL PROTECTION; STREPTOZOCIN DIABETES; TREATMENT RESPONSE; ANIMAL; DRUG ANTAGONISM; HUMAN; MOUSE; RAT;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; AMIDES; ANIMALS; DIABETIC NEPHROPATHIES; HUMANS; MICE; PROTEIN KINASE INHIBITORS; PYRIDINES; RATS; RHO-ASSOCIATED KINASES;

EID: 40949113247     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-1768     Document Type: Note

References (12)

1. Vega FM, Ridley AJ: Snapshot: Rho family GTPases. Cell 129:1430, 2007
2. Hayashi K, Wakino S, Kanda T, Homma K, Sugano N, Sarata T: Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-Mnase in the development of renal injury. J Pharmacol Sci 100:29-33, 2006
3. Budzyn K, Marley PD, Sobey CG: Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol Sci 27:97-104, 2006
4. Sharpe CC, Hendry BM: Signaling: focus on Rho in renal disease. J Am Soc Nephrol 14:261-264, 2003
5. Massey AR, Miao L, Smith BN, Liu J, Kusaka I, Zhang JH, Tang J: Increased RhoA translocation in renal cortex of diabetic rats. Life Sci 72:2943-2952, 2003
6. Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S, Sahai A, Kanwar YS: 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci USA 99:8301-8305, 2002
7. Kikuchi Y, Yamada M, Imakiire T, Kushiyama T, Higashi K, Hyodo N, Yamamoto K, Oda T, Suzuki S, Miura S: A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol 192:595-603, 2007
8. Gojo A, Utsunomiya K, Taniguchi K, Yokota T, Ishizawa S, Kanazawa Y, Kurata H, Tajima N: The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol 568:242-247, 2007
9. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR: Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 57:714-723, 2008
10. Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95-105, 2000
11. Campese VM, Park J: HMG-CoA reductase inhibitors and the kidney. Kidney Int 71:1215-1222, 2007
12. Shimokawa H, Rashid M: Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci 28:296-302, 2007